Our findings suggest a possible association between additional TERT promoter mutations, alongside low TDS and SLC5A5 mRNA expression in NTRK-rearranged metastatic RAI-resistant thyroid cancers and the re-induction failure of RAI uptake following larotrectinib treatment. The gene discussed is TERT; the disease is thyroid cancer.